81 results
Page 2 of 5
8-K
EX-1.1
xb8yz anlvbwzl18
31 Mar 23
Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock
5:27pm
424B5
akj5cn7pt5rxs3o7z
31 Mar 23
Prospectus supplement for primary offering
5:24pm
424B5
nl46zp5agkd9dzwr
29 Mar 23
Prospectus supplement for primary offering
4:01pm
8-K
EX-99.1
byjarxqgl0msf
26 Oct 22
Viking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:32pm
8-K
EX-99.1
fmxq i66c0p
27 Jul 22
Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:11pm
8-K
EX-99.1
ud5t5j5bx7xpiu3ybad1
27 Apr 22
Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:44pm
8-K
EX-99.1
ltdktt2v6b9s9hxna
9 Feb 22
Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
4:15pm
8-K
EX-99.1
4371y
3 Nov 21
Viking Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
4:10pm
424B5
ddoxlo0onr 2nhji
11 Aug 21
Prospectus supplement for primary offering
4:44pm
8-K
EX-99.1
en3otw7qr
28 Jul 21
Viking Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
4:12pm
8-K
EX-99.1
df0rd
28 Apr 21
Viking Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
4:10pm